Selectively targeting inosine monophosphate dehydrogenase-2 impairs brain metastatic potential while preserving immune cell function

Избирательная мишень: инозинмонофосфатдегидрогеназа-2 снижает метастатический потенциал в мозг при сохранении функции иммунных клеток
Agata Kieliszek, Ariana Huebner, Sheila Kumari Singh, Chitra Venugopal, Laura Escudero, Oliver A. Kent, Petar Miletic, Daniel Mobilio, Shawn C. Chafe, Kui Zhai, Janek Szychowski, Erika Apel, Suky Zheng, Mathew Piotrowski, Danny Chui, Sébastien Alazet, Saeideh Shamsi, Jarrod W. Johnson, Kurt Vandevoorde, Lin Mei, Mariana Acevedo, Juliette Sabbatani, Fatemeh Dordahan, Arun Yadav, Bruce MacKay, Kévin Leguay, Kathleen J Berger, Kui Zhai, P T Ang, Ariana Huebner, Claudio Sturino, Joseph Mancini, Amie L. Phinney, Jakob Magolan, Mathew L Piotrowski, Patrick Ang
2026-06-17

IMPDH2IMPDH2-selective inhibitorsOsimertinib synergybrain metastasisbrain metastasis-initiating cells
Brain metastases (BM) occur in 26% of cancer patients and have a 90% mortality rate within 1 y of diagnosis, yet the current standard of care remains palliative. We have previously shown that de novo GTP synthesis is a druggable metabolic vulnerability in BM cells, through its rate-limiting enzyme, inosine monophosphate dehydrogenase (IMPDH). IMPDH inhibitors have progressed to phase-II oncology trials in the past, failing largely due to dose-limiting toxicities associated with off-target inhibition of IMPDH1, the constitutively expressed isoenzyme in normal human lymphocytes. Here, we determined that a single subtype (isoenzyme) of IMPDH, IMPDH2, is specifically upregulated in brain metastasis-initiating cells (BMICs), absent in normal brain tissue, and is sufficient to drive the formation of BM. Moreover, we show that genetic knockout of IMPDH2 stops the proliferation of BM cells in vitro and the onset of BM in vivo. We synthesized IMPDH2-selective compounds and showed that they maintain a potent antiproliferation effect on BMICs, but spare immune cell function compared to previously developed pan-IMPDH inhibitors. Furthermore, we introduce a positive correlation between compound selectivity for IMPDH2 and the ability to synergize with Osimertinib: the standard of care for EGFR-mutant non-small cell lung cancer. Overall, our results suggest that specifically blocking IMPDH2 is an effective therapeutic strategy for BM by overcoming the immune suppressive effects that have hindered the clinical development of pan-IMPDH inhibitors in the past. An IMPDH2 specific therapy could be coadministered with primary tumor standard of care treatments to provide a safe and interceptional approach for BM.
1
Greater selectivity for IMPDH2 correlates with improved synergy with Osimertinib, the standard of care for EGFR-mutant non-small cell lung cancer
2
IMPDH2 is specifically upregulated in brain metastasis-initiating cells (BMICs) and absent in normal brain tissue
3
IMPDH2 is sufficient to drive brain metastasis formation, and genetic knockout of IMPDH2 halts BM cell proliferation in vitro and BM onset in vivo
4
IMPDH2-selective compounds potently inhibit BMIC proliferation while preserving immune cell function compared to pan-IMPDH inhibitors
5
Targeting IMPDH2 specifically could overcome immune-suppressive toxicities of pan-IMPDH inhibitors and enable safe coadministration with primary tumor therapies for BM interception

Inosine monophosphate dehydrogenase 2 (IMPDH2) in brain metastasis-initiating cells and brain metastases

The effects of selective targeting/inhibition or genetic knockout of IMPDH2 on BM cell proliferation and brain metastasis formation, immune cell function sparing compared to pan-IMPDH inhibition, and synergy with Osimertinib

Publication Details
Publication Date
2026-06-17
Journal
Publisher
ISSN
Cited by
0
Access Type
Author Information
Authors
Agata Kieliszek
Ariana Huebner
Sheila Kumari Singh
Chitra Venugopal
Laura Escudero
Oliver A. Kent
Petar Miletic
Daniel Mobilio
Shawn C. Chafe
Kui Zhai
Janek Szychowski
Erika Apel
Suky Zheng
Mathew Piotrowski
Danny Chui
Sébastien Alazet
Saeideh Shamsi
Jarrod W. Johnson
Kurt Vandevoorde
Lin Mei
Mariana Acevedo
Juliette Sabbatani
Fatemeh Dordahan
Arun Yadav
Bruce MacKay
Kévin Leguay
Kathleen J Berger
Kui Zhai
P T Ang
Ariana Huebner
Claudio Sturino
Joseph Mancini
Amie L. Phinney
Jakob Magolan
Mathew L Piotrowski
Patrick Ang
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%